SLC5A2 and bacterial urinary tract infection: Furthermore, UTI incidence in the SGLT2 inhibitor group (11% in kidney transplant recipients) was lower than that reported in the general diabetic population treated with SGLT2 inhibitors (approximately 34%) [49].